title: Effect of nesiritide in isolated right ventricular failure secondary to pulmonary hypertension.
abstract: Treatment of right ventricular failure (RVF) can be challenging due to the correlation between RVF and worsening renal function with diuretic therapy. Nesiritide has been studied in patients with left ventricular failure but has not been evaluated in isolated RVF. The authors retrospectively analyzed 140 patients admitted with RVF, pulmonary hypertension (PH), and preserved left ventricular systolic function. Seventy patients were treated with nesiritide while the remaining patients received only furosemide (no nesiritide group). Serum creatinine and GFR at baseline, 72 hours, discharge, and 1 month post-treatment, as well as hemodynamic data were compared between the groups. In the nesiritide group, there was a significant decrease in mean GFR (42.77±25.33, P<.001) at day of discharge and 1 month post-nesiritide infusion (41.17±24.94, P<.001) but not in the no nesiritide group. There was a significant difference in >25% decrease in GFR anytime through day 30 (47.14% vs. 25.71%, P=.036) between the two groups. On multivariate analysis, nesiritide remained an important predictor of renal function at discharge and at 1 month (P<.01) as well as a predictor of >25% decrease in GFR anytime through day 30 (P=.007). Thus, nesiritide is associated with worsening kidney function in patients with RVF in the setting of PH.
authors.affiliation: Department of Medicine, Division of Cardiology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY 10467, USA. ikelesid@montefiore.org
authors.forename: Iosif
authors.initials: I
authors.lastname: Kelesidis
authors.forename: Jeremy A
authors.initials: JA
authors.lastname: Mazurek
authors.forename: Wajeeha
authors.initials: W
authors.lastname: Saeed
authors.forename: Ronak
authors.initials: R
authors.lastname: Chaudhari
authors.forename: Pradnya
authors.initials: P
authors.lastname: Velankar
authors.forename: Ronald
authors.initials: R
authors.lastname: Zolty
mesh_terms: D000368:Aged; D016022:Case-Control Studies; D003404:Creatinine / Q000097:blood; D005260:Female; D006333:Heart Failure / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D006976:Hypertension, Pulmonary / Q000150:complications*; D007677:Kidney Function Tests; D008297:Male; D008875:Middle Aged; D045283:Natriuretic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D020097:Natriuretic Peptide, Brain / Q000008:administration & dosage / Q000627:therapeutic use*; D051437:Renal Insufficiency / Q000150:complications / Q000188:drug therapy*; D012189:Retrospective Studies; D018497:Ventricular Dysfunction, Right / Q000150:complications / Q000188:drug therapy*
chemical_list: D045283:Natriuretic Agents; D020097:Natriuretic Peptide, Brain; D003404:Creatinine